Profile data is unavailable for this security.
About the company
SNDL Inc. is a Canada-based private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, Superette and Firesale. The Company is specializing in low-cost biomass sourcing, indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Spiritleaf Selects Bon Jak, Versus, Value Buds, Namaste, Re-up, Grasslands and Vacay. Its segments include Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. Its Liquor retail segment includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail segment includes the private sale of adult-use cannabis through owned and franchised retail cannabis stores. Its Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export.
- Revenue in USD (TTM)672.06m
- Net income in USD-83.20m
- Incorporated2006
- Employees2.52k
- LocationSNDL Inc919 11 AVENUE SW, SUITE 300Calgary T2R1P3CanadaCAN
- Phone+1 (403) 948-5227
- Fax+1 (403) 948-5227
- Websitehttps://www.sndl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Therapeutics Inc | 277.79m | -98.50m | 329.66m | 240.00 | -- | -- | -- | 1.19 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 353.83m | 1.60k | -- | 0.897 | -- | 0.321 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 391.87m | 99.00 | -- | 2.02 | -- | 6.32 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 398.44m | 64.00 | 19.50 | 6.84 | 18.92 | 6.00 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| CorMedix Inc | 806.12k | -53.12m | 412.25m | 82.00 | -- | 8.83 | -- | 511.40 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 424.10m | 65.00 | -- | 10.42 | -- | 17.68 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 436.57m | 377.00 | -- | -- | -- | 2.41 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 453.33m | 150.00 | -- | 2.62 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 463.49m | 135.00 | -- | -- | -- | 7.94 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 476.85m | 121.00 | -- | 2.04 | -- | 9.46 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| SNDL Inc | 672.06m | -83.20m | 527.50m | 2.52k | -- | 0.5812 | -- | 0.7849 | -0.3185 | -0.3185 | 2.56 | 3.42 | 0.5988 | 4.63 | 33.15 | 267,115.60 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| SIGA Technologies Inc | 172.96m | 83.97m | 601.64m | 45.00 | 7.25 | 3.59 | 7.12 | 3.48 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Revance Therapeutics Inc | 243.90m | -283.87m | 605.29m | 597.00 | -- | -- | -- | 2.48 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Pacira Biosciences Inc | 690.31m | 63.59m | 670.22m | 711.00 | 12.42 | 0.7621 | 4.86 | 0.9709 | 1.17 | 1.17 | 12.34 | 19.07 | 0.4329 | 1.83 | 6.77 | 970,900.10 | 3.99 | 3.35 | 4.26 | 3.98 | 74.05 | 72.63 | 9.21 | 8.57 | 5.70 | -- | 0.4013 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Pliant Therapeutics Inc | 0.00 | -185.41m | 738.13m | 158.00 | -- | 1.87 | -- | -- | -3.09 | -3.09 | 0.00 | 6.50 | 0.00 | -- | -- | 0.00 | -35.03 | -33.24 | -37.15 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0711 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Data as of Sep 20 2024. Currency figures normalised to SNDL Inc's reporting currency: US Dollar USD
8.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tidal Investments LLCas of 30 Jun 2024 | 6.20m | 2.34% |
| Cannell Capital LLCas of 30 Jun 2024 | 4.71m | 1.78% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.69m | 1.02% |
| Millennium Management LLCas of 30 Jun 2024 | 2.08m | 0.79% |
| Global X Management Co. LLCas of 30 Jun 2024 | 1.87m | 0.71% |
| Global X Investments Canada, Inc.as of 31 Aug 2024 | 1.80m | 0.68% |
| AdvisorShares Investments LLCas of 30 Jun 2024 | 1.41m | 0.53% |
| Invesco Capital Management LLCas of 30 Jun 2024 | 793.20k | 0.30% |
| Arrowstreet Capital LPas of 30 Jun 2024 | 787.12k | 0.30% |
| Two Sigma Investments LPas of 30 Jun 2024 | 724.95k | 0.27% |
More ▼
Data from 30 Jun 2024 - 16 Sep 2024Source: FactSet Research Systems Inc.
